»Point-of-care Testing« Vollblutmethoden in der Hämostasediagnostik

Zusammenfassung

Point-of-care-Tests (POCT) mit Vollblut gibt es für verschiedene Analysen im Bereich der Hämostase. Am häufigsten wird die Thromboplastinzeit mit Kapillarblut durchgeführt. Diese POCT-Analyse ist zuverlässig und wird u. a. bei der Patientenselbstkontrolle der oralen Antikoagulation eingesetzt. Die aPTT als POCT ist teilweise problematisch, deren Einsatz muß kritisch erwogen werden. Der PFA-100-Analyser ist geeignet als Screeningtest für Thrombozytopathien und ausgeprägte Von-Willebrand-Faktor-Mangelzustände. Die D-Dimer-Teste mit Vollblut erfüllen die Anforderungen bezüglich hoher Sensitivität nicht immer.

Die Einsatzmöglichkeiten der Hämostase-POCT-Analysen müssen kritisch und wissenschaftlich definiert werden. Diverse Aspekte wie Qualitätskontrolle, Kosten und Gewinnung der Vollblut-Proben müssen weiter bearbeitet werden.

Summary

Several point-of-care tests (POCT) or near patient testing systems using whole blood are now available for hemostasis tests. Determination of the prothrombin time is accurate and safe using these systems. More studies, however, are necessary to define the place of the POCT activated partial thromboplastin time in monitoring heparin therapy. The PFA-100 analyzer is a valuable tool for the detection of platelet function disorders and von Willebrand disease. There are potential problem areas in POCT, such as quality control, costs and blood sample collection and handling which need more work to be done.

Schlüsselwörter

Point-of-care-Tests - Hämostase - Vollblutmethoden

Keywords

Point-of-care testing - hemostasis - near patient testing

• Literatur

• 1 Machin SJ, Mackie IJ, Chitolie A, Lawrie AS. Near patient testing (NPT) in haemostasis – a synoptic review. Clin Lab Haem 1996; 18: 69-74.
• 2 Oberhardt BJ. Thrombosis and Hemostasis testing at the point of care. Am J Clin Pathol 1995; 104: S72-8.
• 3 Kendall J, Reeves B, Clancy M. Point of care testing: randomised controlled trial of clinical outcome. BMJ 1998; 316: 1052-7.
• 4 Wuillemin WA, Burri S, Lämmle B. Quick-Messungen aus Kapillar-Blut mittels CoaguChek oder CoaguChek Plus. Labolife 1997; 3: 1-4.
• 5 Kitchen S, Preston FE. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. J Clin Pathol 1997; 50: 951-6.
• 6 Burri S, Demarmels Biasiutti F, Lämmle B, Wuillemin WA. Vergleich der Quick-/INR-Werte aus kapillärem Vollblut (CoaguChek Plus) und venösem Citratplasma bei Patienten mit und ohne orale Antikoagulation. Schweiz Med Wochenschr 1998; 128: 1723-9.
• 7 Cachia PG, McGregor E, Adlakha S, Davey P, Goudie BM. Accuracy and precision of the TAS analyser for near-patient INR testing by non-pathology staff in the community. J Clin Pathol 1998; 51: 68-72.
• 8 Müller-Beissenhirtz W, Deickert F, Lang H, Schöndorf T, Spanuth E, Taborski U, Witt I. Selbstkontrolle der oralen Antikoagulation: Standortbestimmung. J Lab Med 1997; 21: 558-62.
• 9 Arbeitsgemeinschaft Selbstkontrolle der Antikoagulation: Standards und Informationen. Bernardo A, Taborski U, Wittstamm FJ. (Hrsg.). Bad Nauheim: Eigenverlag; 4. Aufl.. 1996
• 10 Solomon HM, Mullins RE, Lyden P, Thompson P, Hudoff S. The diagnostic accuracy of bedside and laboratory coagulation. Procedures used to monitor the anticoagulation status of patients treated with heparin. Am J Clin Pathol 1998; 109: 371-8.
• 11 Werner M, Gallagher JV, Ballo MS, Karcher DS. Effect of analytic uncertainty of conventional and point-of-care assays of activated partial thromboplastin time on clinical decisions in heparin therapy. Am J Clin Pathol 1994; 102: 237-41.
• 12 Hézard N, Metz D, Potron G, Nazeyrollas P, Maes D, Droulle C, Mulpas MC, Elaerts J, Nguyen P. Monitoring the effect of heparin bolus during percutaneous coronary angioplasty (PTCA): assessment of three bedside coagulation monitors. Thromb Haemost 1998; 80: 865-6.
• 13 The Investigators GUSTO-I. Use of bedside activated partial thromboplastin time monitor to adjust heparin dosing after thrombolysis for acute myocardial infarction: results of GUSTO-I. Am Heart J 1998; 136: 868-76.
• 14 Patel VB, Moliterno DJ. Bedside activated partial thromboplastin time monitoring: just a matter of time?. Am Heart J 1999; 137: 8-11.
• 15 Kolde HJ, de Haan J. Eine neue Methode zur Bestimmung der Plättchenhämostasekapazität. Erfahrungen aus klinischen Studien. Hämostaseologie 1998; 18: 41-8.
• 16 Fressinaud E, Veyradier A, Truchaud F, Martin I, Boyer-Neumann C, Trossaert M, Meyer D. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998; 91: 1325-31.
• 17 Harrison P, Robinson MSC, Mackie IJ, Joseph J, McDonald SJ, Liesner R, Savidge GF, Pasi J, Machin SJ. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary haemostasis. Blood Coag Fibrinol 1999; 10: 25-31.
• 18 Coller BS. Monitoring platelet GPIIb/IIIa antagonist therapy. Blood Coag Fibrinol 1999; 10: S81-6.
• 19 Smith JW, Steinhubl SR, Lincoff AM, Coleman JC, Lee TT, Hillman RS, Coller BS. Rapid platelet-function assay. An automated and quantitative cartridge-based method. Circulation 1999; 99: 620-5.
• 20 Boldt J, Walz G, Triem J, Suttner S, Kumle B. Point-of-care (POC) measurement of coagulation after cardiac surgery. Intensive Care Med 1998; 24: 1187-93.
• 21 Ereth MH, Nuttal GA, Santrach PJ, Klindworth JT, Oliver Jr WC, Schaff HV. The relation between the platelet-activated clotting test (Hemostatus) and blood loss after cardiopulmonary bypass. Anesthesiology 1998; 88: 962-9.
• 22 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. Anesth Analg 1999; 88: 312-9.
• 23 Stammers AH, Bruda NL, Gonano C, Hartmann T. Point-of-care coagulation monitoring: applications of the thromboelastograph. Anaesthesia 1998; 53: 58-9.
• 24 Despotis GJ, Joist JH, Goodnough LT. Monitoring of hemostasis in cardiac surgical patients: impact of point-of-care testing on blood loss and transfusion outcomes. Clin Chem 1997; 43: 1684-96.
• 25 Lind SE. The bleeding time does not predict surgical bleeding. Blood 1991; 77: 2547-52.
• 26 John MA, Elms MJ, O’Reilly EJ, Rylatt DB, Bundesen PG, Hillyard CJ. The SimpliRED D-dimer test: a novel assay for the detection of cross-linked fibrin degradation products in whole blood. Thromb Res 1990; 58: 273-81.
• 27 Bounameaux H, De Moerloose P, Perrier A, Miron M-J. D-dimer testing in suspected venous thromboembolism: an update. Q J Med 1997; 90: 437-42.
• 28 Mauron T, Baumgartner I, Z’Brun A, Demarmels-Biasiutti F, Redondo M, Do DD, Lämmle B, Wuillemin WA. SimpliRED D-dimer assay: comparability of capillary and citrated venous whole blood, between-assay variability, and performance of the test for exclusion of deep vein thrombosis in symptomatic outpatients. Thromb Haemost 1998; 79: 1217-9.
• 29 Kessler CM, Bernstein Z, Ghesani S, Shamsipour Z, Frances C, Zucker ML, LaDuca FM. Bedside Measurement of Factor VIII:C activity in individuals with Hemophilia A. Am J Hematol 1996; 51: 181-5.
• 30 Kane B. Point-of-care testing: instant gratification?. Ann Int Med 1999; 130: 870-2.
• 31 BCSH. Guide-lines for near patient testing: haematology. Clin Lab Haem 1995; 17: 301-10.